Literature DB >> 28446612

CDK4 protein is degraded by anaphase-promoting complex/cyclosome in mitosis and reaccumulates in early G1 phase to initiate a new cell cycle in HeLa cells.

Huabo Chen1, Xiaowei Xu1, Guopeng Wang1, Boyan Zhang1, Gang Wang1, Guangwei Xin1, Junjun Liu2, Qing Jiang3, Hongyin Zhang4, Chuanmao Zhang5.   

Abstract

CDK4 regulates G1/S phase transition in the mammalian cell cycle by phosphorylating retinoblastoma family proteins. However, the mechanism underlying the regulation of CDK4 activity is not fully understood. Here, we show that CDK4 protein is degraded by anaphase-promoting complex/cyclosome (APC/C) during metaphase-anaphase transition in HeLa cells, whereas its main regulator, cyclin D1, remains intact but is sequestered in cytoplasm. CDK4 protein reaccumulates in the following G1 phase and shuttles between the nucleus and the cytoplasm to facilitate the nuclear import of cyclin D1. Without CDK4, cyclin D1 cannot enter the nucleus. Point mutations that disrupt CDK4 and cyclin D1 interaction impair the nuclear import of cyclin D1 and the activity of CDK4. RNAi knockdown of CDK4 also induces cytoplasmic retention of cyclin D1 and G0/G1 phase arrest of the cells. Collectively, our data demonstrate that CDK4 protein is degraded in late mitosis and reaccumulates in the following G1 phase to facilitate the nuclear import of cyclin D1 for activation of CKD4 to initiate a new cell cycle in HeLa cells.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  cell cycle; cyclin D1; cyclin-dependent kinase (CDK); protein degradation; retinoblastoma protein (pRb, RB)

Mesh:

Substances:

Year:  2017        PMID: 28446612      PMCID: PMC5473219          DOI: 10.1074/jbc.M116.773226

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

Review 1.  Recycling the cell cycle: cyclins revisited.

Authors:  Andrew W Murray
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

Review 2.  The regulation of E2F by pRB-family proteins.

Authors:  N Dyson
Journal:  Genes Dev       Date:  1998-08-01       Impact factor: 11.361

Review 3.  Cyclin D as a therapeutic target in cancer.

Authors:  Elizabeth A Musgrove; C Elizabeth Caldon; Jane Barraclough; Andrew Stone; Robert L Sutherland
Journal:  Nat Rev Cancer       Date:  2011-07-07       Impact factor: 60.716

4.  New functional activities for the p21 family of CDK inhibitors.

Authors:  J LaBaer; M D Garrett; L F Stevenson; J M Slingerland; C Sandhu; H S Chou; A Fattaey; E Harlow
Journal:  Genes Dev       Date:  1997-04-01       Impact factor: 11.361

5.  Cyclin D1 production in cycling cells depends on ras in a cell-cycle-specific manner.

Authors:  M Hitomi; D W Stacey
Journal:  Curr Biol       Date:  1999-10-07       Impact factor: 10.834

6.  Securin degradation is mediated by fzy and fzr, and is required for complete chromatid separation but not for cytokinesis.

Authors:  A Zur; M Brandeis
Journal:  EMBO J       Date:  2001-02-15       Impact factor: 11.598

7.  A single amino acid change converts Aurora-A into Aurora-B-like kinase in terms of partner specificity and cellular function.

Authors:  Jingyan Fu; Minglei Bian; Junjun Liu; Qing Jiang; Chuanmao Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-08       Impact factor: 11.205

8.  Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells.

Authors:  Chioniso Patience Masamha; Doris Mangiaracina Benbrook
Journal:  Cancer Res       Date:  2009-07-28       Impact factor: 12.701

9.  D-type cyclin-dependent kinase activity in mammalian cells.

Authors:  H Matsushime; D E Quelle; S A Shurtleff; M Shibuya; C J Sherr; J Y Kato
Journal:  Mol Cell Biol       Date:  1994-03       Impact factor: 4.272

Review 10.  The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention.

Authors:  John P Alao
Journal:  Mol Cancer       Date:  2007-04-02       Impact factor: 27.401

View more
  13 in total

1.  Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A.

Authors:  Elizabeth A Mazzio; Karam F A Soliman
Journal:  Cancer Genomics Proteomics       Date:  2018 Sep-Oct       Impact factor: 4.069

2.  The DNA deaminase APOBEC3B interacts with the cell-cycle protein CDK4 and disrupts CDK4-mediated nuclear import of Cyclin D1.

Authors:  Jennifer L McCann; Madeline M Klein; Evelyn M Leland; Emily K Law; William L Brown; Daniel J Salamango; Reuben S Harris
Journal:  J Biol Chem       Date:  2019-06-19       Impact factor: 5.157

3.  Dysregulated endolysosomal trafficking in cells arrested in the G1 phase of the host cell cycle impairs Salmonella vacuolar replication.

Authors:  Clivia Lisowski; Jane Dias; Susana Costa; Ricardo Jorge Silva; Miguel Mano; Ana Eulalio
Journal:  Autophagy       Date:  2021-11-15       Impact factor: 13.391

4.  Expression Of Cyclin D1 Protein Isoforms And Its Prognostic Significance In Cervical Cancer.

Authors:  Jiahui Gu; Xinyu Zhang; Zhuo Yang; Ning Wang
Journal:  Cancer Manag Res       Date:  2019-10-24       Impact factor: 3.989

5.  Activation of MAPK and Cyclin D1/CDK4 in Malignant Transformation of Human Embryonic Lung Fibroblasts Induced by Silica and Benzopyrene.

Authors:  Huan Wang; Shuyu Xiao; Yali Tang; Ke Han; Zheng Zhang; Yulan Jin; Fuhai Shen
Journal:  Asian Pac J Cancer Prev       Date:  2020-02-01

6.  Cyclin D1 Stability Is Partly Controlled by O-GlcNAcylation.

Authors:  Louis Masclef; Vanessa Dehennaut; Marlène Mortuaire; Céline Schulz; Maïté Leturcq; Tony Lefebvre; Anne-Sophie Vercoutter-Edouart
Journal:  Front Endocrinol (Lausanne)       Date:  2019-02-22       Impact factor: 5.555

7.  Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth.

Authors:  Celine Bouclier; Matthieu Simon; Guillaume Laconde; Morgan Pellerano; Sebastien Diot; Sylvie Lantuejoul; Benoit Busser; Laetitia Vanwonterghem; Julien Vollaire; Véronique Josserand; Baptiste Legrand; Jean-Luc Coll; Muriel Amblard; Amandine Hurbin; May C Morris
Journal:  Theranostics       Date:  2020-01-12       Impact factor: 11.556

Review 8.  Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia.

Authors:  Raoul Tibes; James M Bogenberger
Journal:  Front Oncol       Date:  2019-12-12       Impact factor: 6.244

9.  Copper Chaperone Atox1 Interacts with Cell Cycle Proteins.

Authors:  Maria Matson Dzebo; Stéphanie Blockhuys; Sebastian Valenzuela; Emanuele Celauro; Elin K Esbjörner; Pernilla Wittung-Stafshede
Journal:  Comput Struct Biotechnol J       Date:  2018-10-31       Impact factor: 7.271

Review 10.  The role of Anaphase Promoting Complex activation, inhibition and substrates in cancer development and progression.

Authors:  Cordell VanGenderen; Troy Anthony Alan Harkness; Terra Gayle Arnason
Journal:  Aging (Albany NY)       Date:  2020-08-15       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.